survey (0) Representative survey of Representative survey of community pharmacy only 500 community dispensing pharmacies Likely to underrepresent private Does not include PGA pharmacies (e.g. discount chains) RACF Webstercare Able to track RACF only unit dose systems (1) dispensing Community systems vary Dose systems established and may not be compatible with the Webstercare Unit Amount procured Hospital pharmacy Most comprehensive Unable to account for or distributed procurement view of total amount actual used (e.g. includes systems (>3) procured (includes loss, discarded imprest stock) stock, ‘shrinkage’ [stolen]) Not linked to patient or ward use (i.e. unable to convert to DDDs) Wholesalers and Provides gross national not directly linked manufacturers sales on AU to use (e.g. lag time from sale to use) Able to be compared internationally by Data not very granular manufacturers (i.e. (interpretation and use allowing international of data from analysis are comparison of drugs limited) under patent) Data commercial in confidence and therefore not publicly available Limited manufacturer data with associated cost for reporting Amount Electronic Contains extensive Very limited clinical administered to the administration clinical data (for scenario patient systems (e.g. ICU and appropriateness of Systems in limited use EMR systems) (>5) therapy and linking to nationally (e.g. only used AMR, etc.) in individual wards) Captures use in clinical Manual medication Enables assessment of Manual data collection is administration clinical appropriateness time intensive and not audit (0) and context always continuous (i.e. point prevalence) Used by NAPS
survey (0) Representative survey of community pharmacy dispensing Representative survey of only 500 community pharmacies Likely to underrepresent private Does not include pharmacies (e.g. discount chains) RACF Webstercare unit dose systems (1) Able to track dispensing Dose systems established RACF only Community systems vary and may not be compatible with the Webstercare Unit Amount procured or distributed Hospital pharmacy procurement systems (>3) Most comprehensive view of total amount procured (includes imprest stock) Unable to account for actual used (e.g. includes loss, discarded stock, ‘shrinkage’ [stolen]) Not linked to patient or ward use (i.e. unable to convert to DDDs) Wholesalers and manufacturers Provides gross national sales on AU Able to be compared internationally by manufacturers (i.e. allowing international comparison of drugs under patent) not directly linked to use (e.g. lag time from sale to use) Data not very granular (interpretation and use of data from analysis are limited) Data commercial in confidence and therefore not publicly available Limited manufacturer data with associated cost for reporting Amount administered to the patient Electronic administration systems (e.g. ICU and EMR systems) (>5) Contains extensive clinical data (for appropriateness of therapy and linking to AMR, etc.) Captures use in clinical Very limited clinical scenario Systems in limited use nationally (e.g. only used in individual wards) Manual medication administration audit (0) Enables assessment of clinical appropriateness and context Used by NAPS Manual data collection is time intensive and not always continuous (i.e. point prevalence) PGA
AURA-Preliminary-Report-Highlights-Doc-Dec-2015-Wed.docx